UPDATE: Lilly reports robust Q4, full-year earnings
Lilly’s fourth-quarter earnings, released before the market opened Thursday, surpassed analysts’ expectations by millions.
Eli Lilly and Co.
Articles
Roche gets FDA clearance for test of emerging cardiovascular disease risk factor
Lipoprotein(a) has long been recognized as a critical marker for people at risk of cardiovascular disease. However, the health care industry has lacked the tools to tackle the problem.
Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.’s Omvoh, a new therapy to treat Chron’s disease and ulcerative colitis, is the company’s latest step into the treatment of gastrointestinal diseases.
New life sciences consortium aims to give Indiana researchers better access to health data
AnalytiXIN has launched a consortium designed to give Indiana researchers better access to health care data—potentially helping Eli Lilly and Co. and other companies develop new medicines more quickly.
Sweeping review looks at effect of weight-loss drugs on 175 conditions
The research is the first to attempt to comprehensively investigate the impact—both good and bad—of the GLP-1 weight-loss drugs on the human body.
Lilly shares fall midday on lower fourth quarter revenue guidance
The company expects fourth-quarter revenue to be about $13.5 billion.
Lilly acquires Scorpion Therapeutics in deal worth up to $2.5B
The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors.
Lilly sees new weight-loss pill approval in early 2026, CEO says
Pills would be more convenient for patients and also easier to manufacture at large scale than other top weight-loss drugs, which require , CEO Dave Ricks said.
Medicaid coverage of weight-loss drugs could cost state up to $70 million a year
The Indiana Family and Social Service Administration’s Office of Medicaid Policy and Planning estimates that 5% to 20% of eligible members would be prescribed weight-loss medications.
State’s big, bold LEAP District play draws some reflection
The state has spent more than $690 million so far establishing the LEAP Research and Innovation District. Outgoing economic leaders say the project is a huge success, but some political leaders are cautious.
2024 Newsmaker: Lilly CEO David Ricks
Ricks—IBJ’s newsmaker of the year in 2023—returns to the newsmaker list in 2024 after a year that included a stock price that skyrocketed to an all-time high of $972 and announcements about big new investments in Lebanon and Ireland.
2024 Year in Review: Lilly’s total investment at LEAP climbs to $13.5B
Lilly said the expansion is expected to add 400 full-time jobs for highly skilled workers, including engineers, scientists, operations personnel and lab technicians.
LEAP district developments among year’s top tech stories
The ongoing progress to develop the planned LEAP Innovation and Research District, a 9,000-acre tech park in Boone County, was among the top local tech stories of 2024.
FDA approves Lilly’s Zepbound for obstructive sleep apnea
Lilly’s stock was up slightly in after-hours trading.
Lilly stock caught up in wave of uncertainty
After a stunning 703% run-up in price over the past five years, shares of Eli Lilly and Co. have been on a roller-coaster ride since September.
Lilly’s U.S. weight-loss drug shortage ends, curtailing copycats
The FDA had previously said Lilly’s drugs were out of shortage and that making copies must cease in October. Compounders sued, causing the FDA to pause enforcement while it reevaluated its decision.
State approves $60M for LEAP District development for Lilly, Meta projects
The state will eventually recoup much of that investment when LEAP land is sold to tenants, officials from the Indiana Economic Development Corp. said.
IEDC requests additional $60M for Lilly, Meta land, infrastructure at LEAP
The state’s job-creation agency is seeking $27 million to purchase about 307 acres and pay for deposits and option payments for additional land west of Interstate 65. Another $33 million is being sought for infrastructure work.
Lilly CEO predicts obesity-treatment Zepbound will become drugmaker’s top drug by 2025
David Ricks told a lunch audience at the Economic Club of Washington, D.C., that Zepbound could quickly become the most popular drug in the 148-year-old company’s history.
Lilly to test obesity drugs for addiction treatment, CEO says
Lilly also approved a program to buy back as much as $15 billion of its own shares amid rapid growth fueled by Zepbound and Mounjaro.